Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
1. Infantino M, Grossi V, Benucci M, Manfredi M. Letter to the Editor relating to Clin Chem Lab Med 2018;56(7):1090–1099. Clin Chem Lab Med 2019;57:e45–6.10.1515/cclm-2018-0599Search in Google Scholar
2. Bonroy C, Schouwers S, Berth M, Stubbe M, Piette Y, Hoffman I, et al. The importance of detecting anti-DFS70 in routine clinical practice: comparison of different care settings. Clin Chem Lab Med 2018;56:1090–9.10.1515/cclm-2017-0541Search in Google Scholar
3. Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: a reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods 2016;436:50–3.10.1016/j.jim.2016.06.008Search in Google Scholar
4. Seelig CA, Bauer O, Seelig HP. Autoantibodies against DFS70/LEDGF exclusion markers for systemic autoimmune rheumatic diseases (SARD). Clin Lab 2016;62:499–517.10.7754/Clin.Lab.2015.150905Search in Google Scholar
5. Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med 2018;5:88. ecollection 2018.10.3389/fmed.2018.00088Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston